Black Patients Miss Out On Promising Cancer Drugs

Style Magazine Newswire | 9/21/2018, 3:49 p.m.
It’s a promising new drug for multiple myeloma, one of the most savage blood cancers. Called Ninlaro, it can be ...

Source: propublica.org

It’s a promising new drug for multiple myeloma, one of the most savage blood cancers. Called Ninlaro, it can be taken as a pill, sparing patients painful injections or cumbersome IV treatments. In a video sponsored by the manufacturer, Takeda Pharmaceutical Co., one patient even hailed Ninlaro as “my savior.” The U.S. Food and Drug Administration approved it in 2015 after patients in a clinical trial gained an average of six months without their cancer spreading. That trial, though, had a major shortcoming: its racial composition. One out of five people diagnosed with multiple myeloma in the U.S. is black, and African Americans are more than twice as likely as white Americans to be diagnosed with the blood cancer. Yet of the 722 participants in the trial, only 13 — or 1.8 percent — were black.